Univeristy of Michigan
Welcome,         Profile    Billing    Logout  
 13 Trials 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Moler, Frank W
ICECAP, NCT05376267: Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-)

Recruiting
N/A
900
Europe, Canada, US, RoW
Therapeutic Hypothermia
University of Michigan, National Heart, Lung, and Blood Institute (NHLBI), Kennedy Krieger Institute, Baltimore, MD
Cardiac Arrest, Out-Of-Hospital, Hypothermia, Induced, Hypoxia-Ischemia, Brain
03/28
03/28
Jolly, Shruti
NCT02492867: A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

Completed
N/A
49
US
Response-driven Adaptive Radiation Therapy, Carboplatin, Paclitaxel, FDG-PET, Positron Emission Tomography Scan, V/Q SPECT, Single-photon Emission Computed Tomography Scan, Durvalumab
University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
11/21
04/22
NCT02045381: Optimization of MRI for Radiation Therapy

Completed
N/A
250
US
MRI Group
University of Michigan Rogel Cancer Center
Cancer Liver, Cancer Brain, Cancer Head &Neck, Cancer Pelvis
02/23
02/23
Feng, Mary
NCT04430452: Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for Liver Cancer After Progression on PD-1 Inhibition

Recruiting
2
21
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Hypofractionated Radiation Therapy, Hypofractionated Radiotherapy, hypofractionation, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
Mary Feng, MD, AstraZeneca
Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8
02/27
02/27
ARM-GI, NCT04221893: Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

Recruiting
N/A
28
US
Radiation Therapy (RT), Cancer Radiotherapy, Irradiate, irradiated, Irradiation, RADIATION, Radiation Therapy, Radiation Therapy, Not otherwise specified, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
University of California, San Francisco, Varian Medical Systems
Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Stage IV Adenocarcinoma of the Gastroesophageal Junction, Stage IVA Esophageal Adenocarcinoma, Stage IVA Esophageal Squamous Cell Carcinoma, Stage IVA Gastric Cancer, Stage IVA Adenocarcinoma of the Gastroesophageal Junction, Stage IVB Esophageal Adenocarcinoma, Stage IVB Esophageal Squamous Cell Carcinoma, Stage IVB Gastric Cancer, Stage IVB Gastroesophageal Junction Adenocarcinoma, Metastatic Anal Canal Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Small Intestinal Carcinoma, Pancreatobiliary Carcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC V8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Anal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8
12/25
11/27
Goutman, Stephen
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated
3
489
Europe, Canada, US, RoW
Reldesemtiv, Placebo
Cytokinetics
Amyotrophic Lateral Sclerosis
07/23
07/23
COURAGE OLE, NCT05442775 / 2021-004727-33: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)

Terminated
3
71
Europe, Canada, US, RoW
Reldesemtiv
Cytokinetics, Cytokinetics Inc
Amyotrophic Lateral Sclerosis
06/23
06/23
Yang, Bo
NCT05622890: A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

Recruiting
3
35
RoW
Mirvetuximab Soravtansine, IMGN853, MIRV
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
04/23
12/23
GQ1005-102, NCT06154343: A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Recruiting
1
150
RoW
GQ1005
GeneQuantum Healthcare (Suzhou) Co., Ltd.
HER2 Expressing or Mutated Advanced Malignant Solid Tumors
12/24
07/25
NCT04450732 / ACTRN12620000592943: Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

Recruiting
1
96
US, RoW
GQ1001
GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd
HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor
03/24
05/24
NCT05782881: High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program

Recruiting
N/A
16000
RoW
phone calls and encouraging patients' lifestyle change and medication adherence, Statin, Angiotensin-converting enzyme inhibitor, Angiotensin receptor neprilysin inhibitor, Glucagon-like peptide-1, Sodium-dependent glucose transporters 2
Wuhan Union Hospital, China, Peking University First Hospital
Cardiovascular Diseases, Diabetes Mellitus, Type 2, Coronary Disease
12/23
12/24
NCT06506903: Avalus Ultra Post-Approval Study (PAS)

Recruiting
N/A
150
US
Medtronic Avalus Ultra
Medtronic Cardiac Surgery
Aortic Valve Disease
11/26
11/26
TITAN:SvS, NCT03536312: Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

Recruiting
N/A
610
Canada, US
Thoracic Aortic Surgery
Ottawa Heart Institute Research Corporation, University of Calgary
Ascending Aortic Aneurysm Enlargement, Ascending Aorta Aneurysm
05/25
05/26
IMPROVE-AD, NCT06087029: IMPRoving Outcomes in Vascular DisEase- Aortic Dissection

Recruiting
N/A
1100
US
TEVAR, Guideline directed medical therapy and surveillance of dissection
Duke University, The University of Texas Health Science Center, Houston, State University of New York - Downstate Medical Center, Oregon Health and Science University, National Heart, Lung, and Blood Institute (NHLBI)
Type B Aortic Dissection
06/30
06/30
NCT01756222: Bicuspid Aortic Valve (BAV) Registry

Recruiting
N/A
5000
US
University of Michigan
Bicuspid Aortic Valve
12/40
12/40
Wubben, Thomas
NCT04671433 / 2020-002873-88: Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Completed
3
97
Europe, Canada, US, RoW
Genetic: AAV5-hRKp.RPGR, botaretigene sparoparvovec
Janssen Research & Development, LLC, Janssen Research & Development, LLC
X-Linked Retinitis Pigmentosa
09/24
09/24
MGT-RPGR-022, NCT04794101 / 2020-002255-37: Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Active, not recruiting
3
97
Europe, Canada, US, RoW
Genetic: AAV5-hRKp.RPGR Intermediate Dose, botaretigene sparoparvovec, Genetic: AAV5-hRKp.RPGR Low Dose
Janssen Research & Development, LLC, Janssen Research & Development, LLC
X-Linked Retinitis Pigmentosa
09/29
12/29
NCT04312672 / 2018-000425-31: Long-term Follow-up Gene Therapy Study for RPGR- XLRP

Active, not recruiting
1/2
42
Europe, US
AAV5-hRKp.RPGR
Janssen Research & Development, LLC, MeiraGTx UK II Ltd, Janssen Research & Development, LLC
X-Linked Retinitis Pigmentosa
11/26
11/26

Download Options